Detection of Residual Leukemic Cells in AML

摘要: Sixty to seventy percent of adult patients with newly diagnosed AML can achieve a complete remission (CR) through intensive chemotherapy [1–6]. However, the majority these will suffer relapse within 2 years. With exception age, secondary leukemias, and small group cytogenetically defined AML, no universelly accepted prognostic marker has been identified which would allow early treatment stratification. Thus is highly uniform, consisting induction chemotherapy, followed by consolidating postremission therapy or without bone marrow transplantation. The “gold standard” for diagnosis monitoring light microscopic evaluation cytology cytochemistry. Its sensitivity detection residual leukemic cells 5%.